Preventing sexual transmission of HIV

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 4, 2007, Pages

  Cohen, Myron S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE PREDISPOSITION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SAFE SEX; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS TRANSMISSION;

DISEASE OUTBREAKS; DISEASE SUSCEPTIBILITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; SAFE SEX; SEXUAL BEHAVIOR;

EID: 40949135763     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522552     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report, 2004. Rev. ed., Vol. 16. Atlanta, GA: US Department of Health and Human Services, CDC, 2006. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2004report/default.htm. Accessed 8 March 2007.
2. Gouws E, White PJ, Stover J, Brown T. Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 2006; 82(Suppl 3):iii51-5.
3. Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report, 2003. Rev. ed., Vol. 15. Atlanta, GA: US Department of Health and Human Services, CDC, 2006. Available at: http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/2003report/default.htm. Accessed 8 March 2007.
4. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-8.
5. Rao KV, Demaris A. Coital frequency among married and cohabiting couples in the United States. J Biosoc Sci 1995; 27:135-50.
6. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42.
7. Wasserheit JN. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
8. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
9. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-92.
10. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391-3.
11. Wawer MJ, Gray RH, Sewankambo D, et al. Rate of HIV transmission per coital act by stage of HIV-1 infection in Rakai, Uganda. J Infect Dis 2005; 191:1403-9.
12. Ahlgren DJ, Gorny MK, Stein AC. Model-based optimization of infectivity parameters: a study of the early epidemic in San Francisco. J Acquir Immune Defic Syndr 1990; 3:631-43.
13. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7:1169-84.
14. Walker PR, Pybus OG, Rambaut A, Holmes EC. Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth. Infect Genet Evol 2005; 5:199-208.
15. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3:23-36.
16. Cohen MS, Shugars DC, Fiscus SA. Limits on oral transmission of HIV-1. Lancet 2000; 356:272.
17. Seidlin M, Vogler M, Lee E, Lee YS, Dubin N. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 1993; 7:1247-54.
18. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-73.
19. Krieger JN, Coombs RW, Collier AC, Ross SO, Speck C, Corey L. Seminal shedding of human immunodeficiency virus type 1 and human cytomegalovirus: evidence for different immunologic controls. J Infect Dis 1995; 171:1018-22.
20. Dyer JR, Eron JJ, Hoffman IF, et al. Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis 1998; 177:224-7.
21. Spinillo A, Zara F, Gardella B, Preti E, Mainini R, Maserati R. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 2005; 192:774-9.
22. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, Montagnier L. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr 1993; 6:72-5.
23. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994; 170:1597-601.
24. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403-7.
25. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
26. Legoff J, Bouhlal H, Lecerf M, et al. HSV-2- and HIV-1-permissive cell lines co-infected by HSV-2 and HIV-1 co-replicate HSV-2 and HIV-1 without production of HSV-2/HIV-1 pseudotype particles. Virol J 2007; 4:2.
27. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513-21.
28. Andreoletti L, Piednoir E, Legoff J, et al. High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients. J Clin Microbiol 2005; 43:4215-7.
29. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-40.
30. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-30.
31. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5:570-5.
32. Hunter DJ. AIDS in sub-Saharan Africa: the epidemiology of heterosexual transmission and the prospects for prevention. Epidemiology 1993; 4:63-72.
33. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
34. Roehr B. Dramatic drop in HIV infections halts circumcision trials. BMJ 2007; 334:11.
35. Critchlow CW, Wolner-Hanssen P, Eschenbach DA, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol 1995; 173:534-43.
36. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-9.
37. Feldblum PJ, Morrison CS, Roddy RE, Cates W Jr. The effectiveness of barrier methods of contraception in preventing the spread of HIV. AIDS 1995; 9(Suppl A):S85-93.
38. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-7.
39. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. BMJ 1992; 304:809-13.
40. Cohen MS, Dallabetta G, Laga M, Holmes KK. A new deal in HIV prevention: lessons from the global approach. Ann Intern Med 1994; 120:340-1.
41. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272-9.
42. Warner L, Clay-Warner J, Boles J, Williamson J. Assessing condom use practices: implications for evaluating method and user effectiveness. Sex Transm Dis 1998; 25:273-7.
43. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-6.
44. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-21.
45. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-21.
46. Kayitenkore K, Bekan B, Rufagari J, et al. The impact of ART on HIV transmission among HIV serodiscordant couples [abstract MOKC101]. In: Program and abstracts the XVIth International AIDS Conference (Toronto, Canada). 2006.
47. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
48. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
49. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
50. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1-20.
51. National Institute of Allergy and Infectious Diseases (NIAID). NIAID HIV Vaccine Trials Network (HVTN). February 2004. Available at: http://www.niaid.nih.gov/factsheets/hvtn.htm. Accessed 8 March 2007.
52. Laumann EO, Masi CM, Zuckerman EW. Circumcision in the United States: prevalence, prophylactic effects, and sexual practice. JAMA 1997; 277:1052-7.